100721-33-3

Basic information

• Product Name: 2-CHLORO-N-CYCLOHEXYL-N-PHENYLACETAMIDE
• Synonyms: 2-CHLORO-N-CYCLOHEXYL-N-PHENYLACETAMIDE
• CAS NO: 100721-33-3
• Molecular Formula: C₁₄H₁₈ClNO
• Molecular Weight: 251.75
• Mol File: 100721-33-3.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 441.6°Cat760mmHg
• Flash Point: 220.8°C
• Appearance: /
• Density: 1.234g/cm³
• Vapor Pressure: 2.4E-05mmHg at 25°C
• Refractive Index: 1.575
• CAS DataBase Reference: 2-CHLORO-N-CYCLOHEXYL-N-PHENYLACETAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-CHLORO-N-CYCLOHEXYL-N-PHENYLACETAMIDE(100721-33-3)
• EPA Substance Registry System: 2-CHLORO-N-CYCLOHEXYL-N-PHENYLACETAMIDE(100721-33-3)

Safety Data

• Hazardous Substances Data: 100721-33-3(Hazardous Substances Data)

Usage

General Description

2-CHLORO-N-CYCLOHEXYL-N-PHENYLACETAMIDE, also known as chlorzoxazone, is a chemical compound used as a muscle relaxant and pain reliever. It works by acting on the central nervous system to reduce muscle tension and provide relief from discomfort. Chlorzoxazone is commonly prescribed to treat muscle spasms and related conditions, such as back pain and injuries. It is available in tablet form and is typically taken orally. Chlorzoxazone should be used cautiously in individuals with liver disease or a history of sensitivities to similar drugs, and it may cause drowsiness, dizziness, and other side effects. Overall, chlorzoxazone is an important medication in the management of musculoskeletal issues and can be an effective option for individuals experiencing muscle-related pain and discomfort.

InChI:InChI=1/C14H18ClNO/c15-11-14(17)16(12-7-3-1-4-8-12)13-9-5-2-6-10-13/h1,3-4,7-8,13H,2,5-6,9-11H2

Upstream product

• 1821-36-9 N-phenyl-2-cyclohexylamine 
• 79-04-9 chloroacetyl chloride 
• 108-94-1 cyclohexanone 
• 62-53-3 aniline 

Downstream Products

• 100722-07-4 iodo-acetic acid-(N-cyclohexyl-anilide) 
• 1452806-97-1 tert-butyl 4-(2-(cyclohexyl(phenyl)amino)-2-oxoethyl)piperazine-1-carboxylate 
• 1452806-94-8 N-cyclohexyl-2-(4-(4-(5-fluoro-1H-indol-3-yl)butyl)piperazin-1-yl)-N-phenylacetamide 
• 1452806-90-4 2-(4-(4-(1H-indol-3-yl)butyl)piperazin-1-yl)-Ncyclohexyl-N-phenylacetamide 
• 1452806-88-0 2-(4-(3-(1H-indol-3-yl)propyl)piperazin-1-yl)-Ncyclohexyl-N-phenylacetamide 
• 1452806-86-8 2-(4-(3-(5-bromo-1H-indol-3-yl)propyl)piperazin-1-yl)-N-cyclohexyl-N-phenylacetamide 
• 1452806-84-6 2-(4-(3-(5-chloro-1H-indol-3-yl)propyl)piperazin-1-yl)-N-cyclohexyl-N-phenylacetamide 
• 684213-06-7 N-cyclohexyl-2-(4-(3-(5-fluoro-1H-indol-3-yl)propyl)piperazin-1-yl)-N-phenylacetamide 
• 1452807-01-0 N-cyclohexyl-N-phenyl-2-(piperazin-1-yl)acetamide 
• 1056991-19-5 2-azido-N-cyclohexyl-N-phenylacetamide 
• 1093975-41-7 N-cyclohexyl-2-{4-[3-methoxy-4-(4-methylimidazol-1-yl)-phenyl]-1,2,3-triazol-1-yl}-N-phenylacetamide 
• 435294-90-9 2-(4-fluorophenylthio)-N-cyclohexyl-N-phenylacetamide 
• 109593-70-6 ethyl-[(cyclohexyl-phenyl-carbamoyl)-methyl]-dimethyl-ammonium; bromide 
• 109848-74-0 [(cyclohexyl-phenyl-carbamoyl)-methyl]-trimethyl-ammonium; iodide 

Relevant articles and documents

Design, Synthesis, and Structure-Activity Relationship Studies of Novel Indolyalkylpiperazine Derivatives as Selective 5-HT1A Receptor Agonists

5-HT1A receptor (5-HT1AR) agonists have been implicated in the treatment of a variety of central nervous system (CNS) diseases such as depression and anxiety, et al. Based on our previously found compound FW01 (Ki = 51 ± 16 nM) obtained by virtual screening, a series of FW01 derivatives were designed and synthesized by the modification of the amide tail group as well as indole headgroup of FW01. SAR exploration found that amide tail group and indole headgroup play pivotal roles in determining the binding affinity and selectivity on dopamine and serotonin receptor subtypes. Among all tested compounds, 9_24 has a Ki value of 5 ± 0.6 nM with a good selectivity toward 5-HT1AR. The [35S] GTPγS assay showed that 9_24 is a full agonist toward 5-HT1AR with an EC50 value of 0.059 nM, which shows 266.2 and 146.4-fold selectivity to 5-HT2A and D3 respectively. Molecular dynamics simulations and molecular docking studies with 5-HT1AR-9_24 were performed to disclose the mechanism of its high activity and selectivity. Finally, a detailed stepwise 9_24 induced signal transduction mechanism of 5-HT1AR is proposed.

Design, synthesis, and evaluation of indolebutylamines as a novel class of selective dopamine D3 receptor ligands

A series of indolebutylamine derivatives were designed, synthesized, and evaluated as a novel class of selective ligands for the dopamine 3 receptor. The most potent compound 11q binds to dopamine 3 receptor with a Ki value of 124 nm and displays excellent selectivity over the dopamine 1 receptor and dopamine 2 receptor. Investigation based on structural information indicates that site S182 located in extracellular loop 2 may account for high selectivity of compounds. Interaction models of the dopamine 3 receptor-11q complex and structure-activity relationships were discussed by integrating all available experimental and computational data with the eventual aim to discover potent and selective ligands to dopamine 3 receptor.

Triazoloamides as potent γ-secretase modulators with reduced hERG liability

Synthesis and SAR studies of novel aryl triazoles as gamma secretase modulators (GSMs) are presented in this communication. Starting from our aryl triazole leads, optimization studies were continued and the series progressed towards novel amides and lactams. Triazole 57 was identified as the most potent analog in this series, displaying single-digit nanomolar Aβ42 IC 50 in cell-based assays and reduced affinity for the hERG channel.